Skip to main content

Table 2 Summary of cardiac safety with trastuzumab in early breast cancer

From: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

TRIAL

ARM

Baseline LEVF(%)

CHF(%)

Cardiac death

Cardiac follow-up

HERA

NIL

>= 55

0

1

MUGA scan or echocardiogram at 3–4 wks prior to randomization, and 3, 6, 12, 18, 24, 30, 36, and 60 mos from randomization

 

H 1 YEAR

 

0.6

0

 

NSABP-31

AC followed P

>= 50

0.8

1

MUGA scan or echocardiogram 3 wks after last AC dose, 6, 9, and 18 mos from randomization, and 3 mos after last trastuzumab dose

 

AC followed PH

 

4.1

0

 

NCCTGN9831

AC followed P

>= 50

0.3

1

MUGA scan 3 wks after last AC dose, 6 and 9 mos from randomization, and 3 mos after the last trastuzumab dose

 

AC followed P and H

 

2.5

1

 
 

AC followed PH

 

3.5

0

 

BCIRG006

AC followed D

>= 50

0.3

0

After last AC dose, after second docetaxel dose, after end of chemotherapy, and at 3, 12 and 36 mos from randomization. At baseline, at 6 wks, 4.5 mos,13.5 mos, and 37.5 mos from randomization

 

AC followed DH

 

1.6

0

 
 

DCarbo followed H

 

0.4

0

 

FIN HER

NO H

>= 50

3

0

MUGA scan or echocardiogram before chemotherapy, after CEF, and 12 and 36 mos after completion of chemotherapy

 

H

 

0

0

 
  1. AC, doxorubicin plus cyclophosphamide; BCIRG, Breast Cancer International ;NCCTG, North Central Cancer Treatment Group; NSABP, National Surgical Adjuvant Breast and Bowel Project; P, paclitaxel. MUGA, multigated acquisition;Research Group; Carbo, carboplatin;CHF, congestive heart failure; cum, cumulative incidence; D, docetaxel; H, trastuzumab; HERA, Herceptin® Adjuvant; LVEF, left ventricular ejection fraction;